Siemens Exhibits Intelligent and Integrated Portfolio of IVD Solutions at AACC Clinical Lab Expo
|
By LabMedica International staff writers Posted on 27 Sep 2021 |
|
Siemens Healthineers (Erlangen, Germany) exhibited its intelligent, integrated range of IVD solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held in Atlanta on September 26-30.
AACC's annual meeting is the world's largest lab medicine conference with nearly 20,000 participants from more than 100 countries. At this year’s AACC, Siemens highlighted its Atellica Solution range of flexible, scalable, automation-ready immunoassay and chemistry analyzers. The Atellica Solution is comprised of sample management, as well as immunoassay and chemistry analyzers, and is an excellent fit for mid-and high-volume labs. It delivers unprecedented flexibility to adapt to changing testing needs and space constraints. The company demonstrated how its Atellica Integrated Automation (AIA) on the Atellica Solution consolidated revolutionary sample management technology, intelligent software, and IT to provide workflow efficiency with the flexibility to add decapping with little or no additional footprint.
Siemens also demonstrated its new, more-scalable automation solutions that include pre- and post-analytics for labs of all sizes to accommodate their specific needs, testing volumes, and resources. Siemens showed how labs could achieve open, one-touch, end-to-end testing with Aptio Automation; Drive open, one-touch sample preparation for multidisciplinary labs with its Atellica Task Targeted Automation; and streamline lab’s biggest chemistry and immunoassay workloads with the Atellica Integrated Automation
Siemens also introduced its new Atellica Hematology Portfolio that pairs analyzers and automation with intelligence to streamline operations and support accurate clinical decision-making that’s on-time, every time. The company displayed two new flagship hematology analyzers - Atellica HEMA 570 and 580 – that are designed to deliver reliable performance targeted for high volume routine workloads.
Siemens is currently developing the Atellica CI 1900 System for the lower-to-mid-volume laboratories. It is planned to utilize the same menu, reagents, consumables, and detection technology as the Atellica Solution2. The Atellica CI 1900 System1 is being designed to take the lab a step beyond by offering the same workflow and IT across the network with the goal of redefining standardization.
Related Links:
Siemens Healthineers
Latest Immunology News
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Channels
Clinical Chemistry
view channel
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more
FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. Reference methods such as equilibrium dialysis with... Read more
Molecular Diagnostics
view channel
Realistic Mock Samples Aim to Speed Cervical Cancer Test Development
Cervical cancer remains highly preventable, yet screening access is limited in many low- and middle-income settings. Gold-standard tests for high-risk human papillomavirus (HPV) detect viral DNA or messenger... Read more
Molecular Marker Identifies Hormone Therapy Resistance Pathway in Prostate Cancer
Most prostate cancers depend on androgen signaling, making hormone suppression or blockade a central treatment strategy. Although many patients respond initially, tumors often adapt and eventually progress,... Read more
Hematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Immunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Microbiology
view channel
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read more
Pathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read more
Technology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more
Industry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more
